North Andover, MA, United States of America

Steven P Langston

This inventor holds 25 USPTO granted patents and 15 published patent applications, plus 8 CIPO patents and 13 EPO patents, primarily in Chemical Compounds. Top assignees: Millennium Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Steven P Langston. Retrieved from https://idiyas.com/inventor/steven-p-langston

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 15)

% Patents Active = 80.0

CIPO Patents = 8

EPO Patents = 13 (Patent Applications = 13)

Average Co-Inventor Count = 7.5

ph-index = 8

Forward Citations = 177(Granted Patents)

Location History:

N. Andover, MA (US) (2016 - 2019)
North Andover, MA (US) (2011 - 2020)
Andover, MA (US) (2017 - 2020)
Cambridge, MA (US) (2023 - 2024)

Company Filing History:

23 out of 855

Millennium Pharmaceuticals Limited

patents

2 out of 1,228

Takeda Pharmaceutical Company Limited

patents

Years Active: 2011-2024

Loading Chart...

Areas of Expertise:

E1 Activating Enzyme

Heteroaryl Compounds

Inhibitors

Pyrazolopyrimidinyl

SUMO Activating Enzyme

Synthesis Process

Sting Modulator

Compounds

Sulfamoylating Reagents

Substituted Pyrrolo

Chemical Methods

Ubiquitin-Activating Enzyme

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054512 - Sting modulator compounds, and methods of making and using (2024-08-06),

2. 11542293 - Sting modulator compounds, and methods of making and using (2023-01-03),

3. 10780090 - Heteroaryl compounds useful as inhibitors of SUMO activating enzyme (2020-09-22),

4. 10745404 - Process for the synthesis of E1 activating enzyme inhibitors (2020-08-18),

5. 10335410 - Heteroaryl compounds useful as inhibitors of sumo activating enzyme (2019-07-02),

6. 10202389 - Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme (2019-02-12),

7. 10016427 - Hydrochloride salt of((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-D]pyrimidin-7-YL}-2-hydroxycyclopentyl) methyl sulfamate (2018-07-10),

8. 9962386 - Heteroaryl compounds useful as inhibitors of SUMO activating enzyme (2018-05-08),

9. 9802938 - Sulfamoylating reagents (2017-10-31),

10. 9796725 - Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme (2017-10-24),

11. 9718788 - Heteroaryl compounds useful as inhibitors of E1 activating enzymes (2017-08-01),

12. 9695154 - Heteroaryl inhibitors of sumo activating enzyme (2017-07-04),

13. 9683003 - Heteroaryl compounds useful as inhibitors of SUMO activating enzyme (2017-06-20),

14. 9663525 - Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme (2017-05-30),

15. 9458108 - Heteroaryl compounds useful as inhibitors of E1 activating enzymes (2016-10-04),

Title: Inventor Spotlight: Steven P. Langston

Introduction

Steven P. Langston, an accomplished inventor based in North Andover, MA, is known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio comprising 25 patents, Langston has focused his research primarily on innovative solutions for medical challenges, particularly in cancer treatment.

Latest Patents

Among his latest patents, Langston has developed groundbreaking STING modulator compounds and methods for their synthesis and use. These STING modulators and agonists aim to provide novel prophylaxis and treatment options for cancer and other STING-related diseases. The disclosures detail a compound characterized by specific formulas, offering promising avenues for pharmaceutical applications.

Career Highlights

Steven P. Langston's professional journey includes impactful roles at renowned companies such as Millennium Pharmaceuticals Limited and Takeda Pharmaceutical Company Limited. His work has significantly influenced the development of novel therapeutic agents, showcasing his expertise in drug formulation and development.

Collaborations

Throughout his career, Langston has collaborated with talented professionals, including Hirotake Mizutani and Stepan Vyskocil. These collaborations have fostered a rich exchange of ideas, contributing to the innovation landscape within the pharmaceutical industry.

Conclusion

As an inventor, Steven P. Langston continues to push the boundaries of pharmaceutical research. His extensive patent portfolio and collaborative efforts illustrate his commitment to advancing medical science and improving patient outcomes. With ongoing research and development, Langston is poised to make lasting impacts in the fight against cancer and related diseases.

Profile summary based on public USPTO records.